• Sun / 1 December 2019 / 10:44
  • Category: Science
  • News Code: 98091006427
  • Journalist : 99999

Discovery of novel seaweed-based drug for diabetes therapy

جلبک دریایی آلژینات

Tehran (ISNA) – A pharmaceutical research team in the school of public health of Tehran University of Medical Sciences (TUMS) has discovered a drug with positive effects on the treatment of type 1 diabetes in the animal phase. This non-steroidal anti-inflammatory drug (NSAID) is passing the necessary stages for obtaining the approval of clinical trial on patients with this disorder.

Seyed Shahabeddin Mortazavi-Jahromi, the researcher of TUMS (immunology department) said in an interview with ISNA: “Drug Guluronic acid (G2013) has been introduced as a new NSAID in an international reputable journal with the cooperation of Italy. Its monomeric form is elicited from a seaweed named Alginate during the acidic hydrolysis process”.

He added: “Tolerability, safety, and efficacy of this drug have been assessed in preclinical studies and also in several clinical trials on patients with rheumatoid arthritis (RA), multiple sclerosis (MS), and ankylosing spondylitis (AS)”.

This researcher continued: “Randomly there are some diabetic patients participating in these clinical trials. Following the observation of the positive effects of drug G2013 on the level of blood glucose of these patients, a distinct investigation was designed on an induced animal model of diabetes, with the discretion of Prof. Mirshafiey, the supervisor of our research team”.

“Treatment of the mice with drug G2013 for 28 days led to a significant reduction of their blood glucose level besides the significant elevation of the insulin level. As incidence risk of atherosclerosis in diabetic patients is 2 to 3.5 times higher than normal individuals, we appraised the expression levels of atherosclerotic inflammatory markers by real-time PCR method and observed that their expression is significantly decreased in G2013-treated group, which is verifying the angio-protective effects of this medication,” Mortazavi-Jahromi stated.

This graduated in cellular and molecular biology notified: there are other drugs with these properties, but the important point is that the drug G2013 has not any side effects. It should be noted that this research project has merely been done in the animal phase and this drug is passing the administrative processes for obtaining the approval of clinical trial on this disease.

End Item

Follow us on Twitter @Isna_Int